Biologics/Immunotherapy News

Baseline and long-term milk component immunoglobulin profiles differed among children based on their responses to milk oral immunotherapy and long-term milk consumption, according to a study published in Allergy.

NASHVILLE, Tenn. — Experts found both consensus and contention during a roundtable discussion of the use of biologics to treat severe asthma, modelled on the ESPN program “Pardon the Interruption,” during the CHEST Annual Meeting.

NASHVILLE, Tenn. — Patients with type 2 inflammatory asthma experienced sustained, long-term reductions in exacerbations and improvements in FEV1 with dupilumab, according to a presentation at the CHEST Annual Meeting.

NASHVILLE, Tenn. — Children aged 6 to 11 years with uncontrolled, moderate to severe type 2 asthma experienced clinical improvements with dupilumab through a 2-year study period, according to a presentation at the CHEST Annual Meeting.

NASHVILLE, Tenn. — Patients on biologic therapies for severe asthma or atopic dermatitis had lower pseudovirus neutralization 6 months after receiving the second dose of mRNA COVID-19 vaccines, according to a study presented at CHEST 2022.

The addition of tezepelumab to subcutaneous allergen immunotherapy for 1 year improved results in nasal allergen challenges for patients with cat allergies, according to a study published in The Journal of Allergy and Clinical Immunology.

Subcutaneous and sublingual immunotherapy for aeroallergens improved disease severity and quality of life among patients with atopic dermatitis, according to a review published in The Journal of Allergy & Clinical Immunology.

Patients with severe asthma who are on subcutaneous immunotherapy for allergy treatment do not experience an increased risk for moderate to severe systemic reactions, according to a study published in Annals of Allergy, Asthma & Immunology.

Patients who received biologic treatment for asthma did not experience higher SARS-CoV-2 infection rates than the general population, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Elevated baseline levels of type 2 biomarkers predicted improved lung function and reduced exacerbation rates with dupilumab among patients with asthma, according to a study in The Journal of Allergy and Clinical Immunology: In Practice.